{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:16:15Z","timestamp":1788264975470,"version":"build-2803163510"},"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clcc.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:31:00Z","timestamp":1786465860000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late Toxicity, Cohort Continuity, and Endpoint Transparency in Triplet Chemoradiotherapy for Anal Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-2313","authenticated-orcid":false,"given":"Elvio Grazioso","family":"Russi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clcc.2026.08.001_bib0001","first-page":"216","article-title":"Randomized phase III study of adding paclitaxel to chemoradiotherapy with capecitabine and mitomycin C in squamous cell anal carcinoma","volume":"25","author":"Gordeyev","year":"2026","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2026.08.001_bib0002","unstructured":"Randomised phase III trial of chemoradiotherapy with or without paclitaxel in patients with squamous-cell anal cancer. NCT02526953. 2026. ClinicalTrials.gov. Accessed June 23, 2026."},{"issue":"4","key":"10.1016\/j.clcc.2026.08.001_bib0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.33878\/2073-7556-2022-21-4-30-38","article-title":"The addition of paclitaxel in chemoradiotherapy of anal squamous cell carcinoma: a prospective randomized phase 3 trial","volume":"21","author":"Gordeyev","year":"2022","journal-title":"Koloproktologi\u00e2"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:36:14Z","timestamp":1788262574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":3,"alternative-id":["S1533002826000526"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.08.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late Toxicity, Cohort Continuity, and Endpoint Transparency in Triplet Chemoradiotherapy for Anal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}